Taxol, Paxene(paclitaxel)
Abraxane, Apealea, Paclitaxel, Pazenir (paclitaxel) is a small molecule pharmaceutical. Paclitaxel was first approved as Taxol on 1992-12-29. It is used to treat breast neoplasms, kaposi sarcoma, non-small-cell lung carcinoma, and ovarian neoplasms in the USA. It has been approved in Europe to treat breast neoplasms, kaposi sarcoma, non-small-cell lung carcinoma, ovarian neoplasms, and pancreatic neoplasms. The pharmaceutical is active against tubulin beta chain. In addition, it is known to target toll-like receptor 4 and nuclear receptor subfamily 1 group I member 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Abraxane, Paclitaxel (discontinued: Paclitaxel, Taxol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Paclitaxel
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PACLITAXEL | American Regent | N-211875 RX | 2022-07-27 | 1 products, RLD, RS |
| ABRAXANE | Bristol Myers Squibb | N-021660 RX | 2005-01-07 | 1 products, RLD, RS |
| PACLITAXEL | Teva | N-216338 RX | 2023-05-11 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| abraxane | New Drug Application | 2022-10-31 |
| paclitaxel | ANDA | 2025-01-24 |
| paclitaxel injection, | ANDA | 2009-07-02 |
| paclitaxel protein bound particles albumin bound | New Drug Application | 2023-05-31 |
| paclitaxel protein-bound particles for injectable suspension (albumin-bound) | NDA authorized generic | 2022-04-01 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Clinical
Clinical Trials
5459 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 235 | 654 | 246 | 27 | 123 | 1159 |
| Non-small-cell lung carcinoma | D002289 | — | — | 186 | 456 | 194 | 10 | 37 | 796 |
| Lung neoplasms | D008175 | — | C34.90 | 151 | 414 | 161 | 9 | 36 | 695 |
| Carcinoma | D002277 | — | C80.0 | 151 | 404 | 101 | 5 | 32 | 628 |
| Neoplasms | D009369 | — | C80 | 380 | 201 | 28 | 4 | 35 | 553 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 143 | 260 | 123 | 3 | 38 | 511 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 193 | 286 | 42 | 3 | 41 | 468 |
| Adenocarcinoma | D000230 | — | — | 128 | 254 | 81 | 3 | 29 | 417 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 101 | 183 | 98 | 3 | 27 | 377 |
| Squamous cell carcinoma | D002294 | — | — | 65 | 248 | 50 | 4 | 23 | 356 |
Show 60 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fallopian tube neoplasms | D005185 | — | — | 61 | 91 | 56 | — | 7 | 193 |
| Uterine cervical neoplasms | D002583 | — | — | 22 | 82 | 44 | — | 20 | 153 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 39 | 64 | 31 | — | 5 | 126 |
| Head and neck neoplasms | D006258 | — | — | 38 | 82 | 12 | — | 3 | 118 |
| Peritoneal neoplasms | D010534 | — | — | 35 | 46 | 29 | — | 5 | 107 |
| Melanoma | D008545 | — | — | 33 | 54 | 11 | — | 1 | 83 |
| Urinary bladder neoplasms | D001749 | — | C67 | 22 | 50 | 8 | — | 2 | 70 |
| Small cell lung carcinoma | D055752 | — | — | 22 | 47 | 7 | — | 2 | 68 |
| Transitional cell carcinoma | D002295 | — | — | 15 | 36 | 13 | — | — | 56 |
| Serous cystadenocarcinoma | D018284 | — | — | 20 | 26 | 18 | — | — | 55 |
Show 137 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | 35 | 25 | — | — | 4 | 49 |
| Lymphoma | D008223 | — | C85.9 | 25 | 12 | — | — | — | 32 |
| Uterine neoplasms | D014594 | EFO_0003859 | C55 | 7 | 15 | — | — | 3 | 22 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 10 | 11 | — | — | 1 | 20 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 11 | 6 | — | — | — | 16 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 7 | 7 | — | — | — | 11 |
| Hemangiosarcoma | D006394 | — | — | 2 | 10 | — | — | — | 11 |
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 3 | 6 | — | — | 1 | 10 |
| Central nervous system neoplasms | D016543 | — | — | 5 | 6 | — | — | 1 | 10 |
| Neuroendocrine carcinoma | D018278 | — | — | 1 | 9 | — | — | — | 9 |
Show 156 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic neoplasms | D019337 | — | — | 7 | — | — | — | — | 7 |
| Hodgkin disease | D006689 | — | C81 | 4 | — | — | — | — | 4 |
| Neutropenia | D009503 | — | D70 | 1 | — | — | — | 3 | 4 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 2 | — | — | — | 1 | 3 |
| Lymphoid leukemia | D007945 | — | C91 | 2 | — | — | — | 1 | 3 |
| Rectal neoplasms | D012004 | — | — | 2 | — | — | — | 1 | 3 |
| Fallopian tube diseases | D005184 | EFO_0009548 | N83 | 2 | — | — | — | 1 | 3 |
| Follicular lymphoma | D008224 | — | C82 | 3 | — | — | — | — | 3 |
| Intestinal neoplasms | D007414 | — | C26.0 | 3 | — | — | — | — | 3 |
| Infections | D007239 | EFO_0000544 | — | 2 | — | — | — | — | 2 |
Show 59 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Popliteal artery entrapment syndrome | D000083082 | — | — | — | — | — | — | 5 | 5 |
| Drug-eluting stents | D054855 | — | — | — | — | — | — | 4 | 4 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 3 | 3 |
| Intracranial arteriosclerosis | D002537 | EFO_1000860 | I67.2 | — | — | — | — | 3 | 3 |
| Balloon angioplasty | D000800 | — | — | — | — | — | — | 3 | 3 |
| Biliary tract diseases | D001660 | EFO_0009534 | K83.9 | — | — | — | — | 3 | 3 |
| Taste disorders | D013651 | — | — | — | — | — | — | 2 | 2 |
| Dysgeusia | D004408 | — | R43.2 | — | — | — | — | 2 | 2 |
| Lower urinary tract symptoms | D059411 | EFO_0008008 | — | — | — | — | — | 2 | 2 |
| Vascular grafting | D058017 | — | — | — | — | — | — | 2 | 2 |
Show 69 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Paclitaxel |
| INN | paclitaxel |
| Description | Paclitaxel is a tetracyclic diterpenoid isolated originally from the bark of the Pacific yew tree, Taxus brevifolia. It is a mitotic inhibitor used in cancer chemotherapy. Note that the use of the former generic name 'taxol' is now limited, as Taxol is a registered trade mark. It has a role as a microtubule-stabilising agent, a metabolite, a human metabolite and an antineoplastic agent. It is a tetracyclic diterpenoid and a taxane diterpenoid. It is functionally related to a baccatin III. |
| Classification | Small molecule |
| Drug class | antineoplastics, taxane derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C |
Identifiers
| PDB | — |
| CAS-ID | 33069-62-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL428647 |
| ChEBI ID | 45863 |
| PubChem CID | 36314 |
| DrugBank | DB01229 |
| UNII ID | P88XT4IS4D (ChemIDplus, GSRS) |
Target
Agency Approved
TUBB
TUBB
Organism
Homo sapiens
Gene name
TUBB
Gene synonyms
TUBB5
NCBI Gene ID
Protein name
tubulin beta chain
Protein synonyms
beta Ib tubulin, epididymis secretory sperm binding protein, tubulin beta-1 chain, Tubulin beta-5 chain, tubulin, beta polypeptide
Uniprot ID
Mouse ortholog
Tubb5 (22154)
tubulin beta-5 chain (Q3UF52)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Abraxane – Bristol Myers Squibb
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Abraxane – Celgene
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 83,595 documents
View more details
Safety
Black-box Warning
Black-box warning for: Abraxane, Paclitaxel, Paclitaxel injection,, Paclitaxel protein bound particles albumin bound, Paclitaxel protein-bound particles for injectable suspension (albumin-bound)
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
95,894 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use